CA19-9 Level to Serum γ-Glutamyltransferase as a Potential Prognostic Biomarker in Patients with Pancreatic Head Carcinoma

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30. doi:10.3322/caac.2144229313949
   PubMed Web of Science ®Google Scholar
• Zhu H, Li T, Du Y, et al. Pancreatic cancer: challenges and opportunities. BMC Med. 2018;16(1):214. doi:10.1186/s12916-018-1215-330463539
   PubMed Web of Science ®Google Scholar
• Bergquist JR, Puig CA, Shubert CR, et al. Carbohydrate Antigen 19-9 elevation in anatomically resectable, early stage pancreatic cancer is independently associated with decreased overall survival and an indication for neoadjuvant therapy: a National Cancer Database Study. J Am Coll Surg. 2016;223(1):52–65. doi:10.1016/j.jamcollsurg.2016.02.00927049786
   PubMed Web of Science ®Google Scholar
• Boeck S, Stieber P, Holdenrieder S, et al. Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer. Oncology. 2006;70(4):255–264.16899980
   PubMed Web of Science ®Google Scholar
• Lee SP, Sung IK, Kim JH, et al. Usefulness of carbohydrate antigen 19-9 test in healthy people and necessity of medical follow-up in individuals with elevated carbohydrate antigen 19-9 level. Korean J Fam Med. 2019;40(5):314–322. doi:10.4082/kjfm.18.005730959581
   PubMed Web of Science ®Google Scholar
• Zhang GM, Bai SM, Zhang GM, et al. Reference intervals of carbohydrate antigen 19-9 in the apparently healthy adult population. J Clin Lab Anal. 2018;32(5):e22380. doi:10.1002/jcla.2238029315815
   PubMed Web of Science ®Google Scholar
• Lin MS, Huang JX, Yu H. Elevated serum level of carbohydrate antigen 19-9 in benign biliary stricture diseases can reduce its value as a tumor marker. Int J Clin Exp Med. 2014;7(3):744–750.24753772
   PubMed Web of Science ®Google Scholar
• Marrelli D, Caruso S, Pedrazzani C, et al. CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions. Am J Surg. 2009;198(3):333–339. doi:10.1016/j.amjsurg.2008.12.03119375064
   PubMed Web of Science ®Google Scholar
• Whitfield JB. Gamma glutamyl transferase. Crit Rev Clin Lab Sci. 2001;38:263–355.11563810
   PubMed Web of Science ®Google Scholar
• Xiao Y, Yang H, Lu J, et al. Serum gamma-glutamyltransferase and the overall survival of metastatic pancreatic cancer. BMC Cancer. 2019;19(1):1020. doi:10.1186/s12885-019-6250-831664937
   PubMed Web of Science ®Google Scholar
• Hlavsa J, Cecka F, Zaruba P, et al. Tumor grade as significant prognostic factor in pancreatic cancer: validation of a novel TNMG staging system. Neoplasma. 2018;65(4):637–643. doi:10.4149/neo_2018_171012N65030064236
   PubMed Web of Science ®Google Scholar
• Barugola G, Partelli S, Crippa S, et al. Time trends in the treatment and prognosis of resectable pancreatic cancer in a large tertiary referral centre. HPB (Oxford). 2013;15(12):958–964. doi:10.1111/hpb.1207323490217
   PubMed Web of Science ®Google Scholar
• O’Brien DP, Sandanayake NS, Jenkinson C, et al. Serum CA19-9 is significantly upregulated up to 2 years before diagnosis with pancreatic cancer: implications for early disease detection. Clin Cancer Res. 2015;21(3):622–631. doi:10.1158/1078-0432.CCR-14-036524938522
   PubMed Web of Science ®Google Scholar
• Sugiura T, Uesaka K, Kanemoto H, et al. Serum CA19-9 is a significant predictor among preoperative parameters for early recurrence after resection of pancreatic adenocarcinoma. J Gastrointest Surg. 2012;16(5):977–985. doi:10.1007/s11605-012-1859-922411488
   PubMed Web of Science ®Google Scholar
• Laurent L, Sefrioui D, Bignon AL, et al. CA19.9 decrease >15% is a predictor of favourable outcome in patients treated for advanced pancreatic carcinoma: analysis of two independent cohorts. HPB (Oxford). 2019;21(5):582–588. doi:10.1016/j.hpb.2018.09.00630466797
   PubMed Web of Science ®Google Scholar
• Rieser CJ, Zenati M, Hamad A, et al. CA19-9 on postoperative surveillance in pancreatic ductal adenocarcinoma: predicting recurrence and changing prognosis over time. Ann Surg Oncol. 2018;25(12):3483–3491. doi:10.1245/s10434-018-6521-729786131
   PubMed Web of Science ®Google Scholar
• Mann DV, Edwards R, Ho S, et al. Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice. Eur J Surg Oncol. 2000;26(5):474–479. doi:10.1053/ejso.1999.092511016469
   PubMed Web of Science ®Google Scholar
• Hanigan MH. Gamma-glutamyl transpeptidase: redox regulation and drug resistance. Adv Cancer Res. 2014;122:103–141.24974180
   PubMed Web of Science ®Google Scholar
• Fu SJ, Zhao Q, Ji F, et al. Elevated preoperative serum gamma-glutamyltranspeptidase predicts poor prognosis for hepatocellular carcinoma after liver transplantation. Sci Rep. 2016;6:28835. doi:10.1038/srep2883527381639
   PubMed Web of Science ®Google Scholar
• Le N, Sund M, Vinci A. GEMS collaborating group of Pancreas 2000. Prognostic and predictive markers in pancreatic adenocarcinoma. Dig Liver Dis. 2016;48(3):223–230. doi:10.1016/j.dld.2015.11.00126769569
   PubMedGoogle Scholar
• Kunutsor SK, Laukkanen JA. Gamma-glutamyltransferase and risk of chronic kidney disease:Aprospective cohort study. Clin Chim Acta. 2017;473:39–44. doi:10.1016/j.cca.2017.08.01428811239
   PubMed Web of Science ®Google Scholar
• Dalos D, Binder C, Duca F, et al. Serum levels of gamma-glutamyltransferase predict outcome in heart failure with preserved ejection fraction. Sci Rep. 2019;9(1):18541. doi:10.1038/s41598-019-55116-831811258
   PubMed Web of Science ®Google Scholar
• Coku V, Shkembi X. Serum Gamma-glutamyltransferase and Obesity: is there a Link? Med Arch. 2018;72(2):112–115. doi:10.5455/medarh.2017.72.112-11529736099
   PubMedGoogle Scholar
• Mei Y, Chen L, Zeng PF, et al. Combination of serum gamma-glutamyltransferase and alkaline phosphatase in predicting the diagnosis of asymptomatic choledocholithiasis secondary to cholecystolithiasis. World J Clin Cases. 2019;7(2):137–144. doi:10.12998/wjcc.v7.i2.13730705891
   PubMed Web of Science ®Google Scholar
• Wang J, Lyu SC, Zhou L, et al. Prognostic analysis of pancreatic carcinoma with portal system invasion following curative resection. Gland Surg. 2021;10(1):35–49. doi:10.21037/gs-20-49533633960
   PubMed Web of Science ®Google Scholar
• Kim M, Kang TW, Cha DI, et al. Prediction and clinical implications of portal vein/superior mesenteric vein invasion in patients with resected pancreatic head cancer: the significance of preoperative CT parameters. Clin Radiol. 2018;73(6):564–573. doi:10.1016/j.crad.2018.01.01629519500
   PubMed Web of Science ®Google Scholar
• Ramacciato G, Nigri G, Petrucciani N, et al. Pancreatectomy with mesenteric and portal vein resection for borderline resectable pancreatic cancer: multicenter study of 406 patients. Ann Surg Oncol. 2016;23(6):2028–2037. doi:10.1245/s10434-016-5123-526893222
   PubMed Web of Science ®Google Scholar